IDYAIDEAYA Biosciences, Inc.
Price
+40%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, growth fading, the market undecided.
We are a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease.
In the company’s own words · 10-K filed Feb 17, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
IDEAYA Biosciences, Inc. (IDYA) reported revenue of $8.9M in Q2 2026 (quarter ended Jun 30, 2026). That came with net loss of $112M. For the full year FY2025, revenue was $219M (+3024% year on year) and net income −$114M. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 4, 2026IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- Jun 23, 2026Effective June 16, 2026, the Company’s Board of Directors (the “Board”) elected Yujiro S. Hata as Chairman of the Board and Terry Rosen, Ph.D., as the Board’s Lead Independent Director.Shareholder vote results · Form 8-K
- Jun 10, 2026Underwriting Agreement On June 8, 2026, IDEAYA Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC, TD Securities (USA) LLC, UBS Securities LLC and Cantor Fitzgerald & Co., as representatives (the “Representatives”) of …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.